In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aridis Pharmaceuticals (ARDS – Research Report), with a price target of $19.00. The company’s shares opened today at $1.03.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 17.1% and a 31.48% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Phio Pharmaceuticals, GeoVax Labs, and Seres Therapeutics.
Aridis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aridis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.24 million. In comparison, last year the company had a GAAP net loss of $21 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Read More on ARDS:
- (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
- Aridis signs deal for commercial licenses for pan-Ebola, pan-Marburg programs
- Aridis Pharmaceuticals closes patient enrollment in Phase 2a study of AR-501
- Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
- Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
